{
  "id": 186636,
  "name": "GLAXOSMITHKLINE",
  "slug": "glaxosmithkline",
  "state": "DC",
  "description": "&#226;€‹Biotechnology pharmaceutical product discovery and development.",
  "totalSpending": 1490000,
  "filings": 30,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 190000
    },
    {
      "year": 2019,
      "income": 250000
    },
    {
      "year": 2020,
      "income": 250000
    },
    {
      "year": 2021,
      "income": 100000
    },
    {
      "year": 2022,
      "income": 200000
    },
    {
      "year": 2023,
      "income": 200000
    },
    {
      "year": 2024,
      "income": 200000
    },
    {
      "year": 2025,
      "income": 100000
    }
  ],
  "firms": [
    "JST STRATEGIES LLC (JOCHUM SHORE & TROSSEVIN PC)"
  ],
  "lobbyists": [
    "DARIN GARDNER",
    "ANDREW SHORE",
    "JAMES JOCHUM",
    "AMBER FAHY",
    "MICHAEL KATZ",
    "EMILY VAUGHAN"
  ],
  "issues": [
    "BUD",
    "HCR",
    null
  ],
  "sampleDescriptions": [
    "Advocacy for expanded access to vaccines.  Advocacy for lupus research within the Department of Defense.  Funding for biosecurity and medical countermeasures.",
    "Part D prescription drug benefit",
    "Drug pricing issues",
    "Drug pricing issues and Operation Warp Speed",
    "drug pricing",
    "Issues related to drug pricing",
    "Prescription drug pricing issues"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -47,
  "trajectory": "reducing",
  "yearsActive": 8,
  "avgAnnualSpending": 186250,
  "peakYear": 2019,
  "lobbyistCount": 6,
  "firmCount": 1,
  "issueCount": 2,
  "industry": "healthcare"
}